Abstract The G1/S phase transition of the cell cycle, controlled by cyclin-dependent kinase 4/6 (CDK4/6), is frequently deregulated in metastatic prostate cancers, establishing a rationale for CDK4/6 inhibition as a therapeutic strategy. However, clinical trials in prostate cancer have shown limited efficacy due to resistance mechanisms that remain unclear.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile